The abstract is read at the publisher; the summary is JClub's.
In 12 lung cancer patients with resistance after EGFR/MET inhibition, 5 (42%) acquired oncogenic fusions, including BRAF, ALK, and RET, highlighting a targetable resistance route.
- Why it matters: Dual EGFR/MET blockade can overcome MET-amplified EGFR TKI resistance, but acquired resistance still emerges and its mechanisms are not well defined.
- What they did: The study established patient-derived cell lines before and after acquired resistance when possible, then used signal pathway analysis and next-generation sequencing to identify resistance alterations.
- The result: EGFR T790M and an ALK fusion responded to subsequent targeted therapies, and in a serial cell-line model, novel IIi-BRAF fusions emerged and osimertinib plus trametinib reversed resistance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.